$3.02
16.48%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US75955J2042
Symbol
RLMD

Relmada Therapeutics Inc Stock price

$3.01
-0.15 4.75% 1M
-3.33 52.52% 6M
-1.82 37.68% YTD
-0.96 24.18% 1Y
+0.21 7.50% 3Y
-18.44 85.97% 5Y
-0.68 18.43% 10Y
-56.99 94.98% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.60 16.62%
ISIN
US75955J2042
Symbol
RLMD
Industry

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$321.2m
Enterprise Value
$103.4m
Net debt
positive
Cash
$217.7m
Shares outstanding
106.7m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
1.6
Financial Health
Equity Ratio
92.0%
Return on Equity
-66.3%
ROCE
-30.8%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$12.9m | -
SBC as % of FCF
-
SBC Growth 1Y
-43.0%
Share Count Growth 1Y
221.4%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-65.1m
Net Income
$-61.9m
Free Cash Flow | ex SBC
$-46.0m | $-58.9m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
7.6%
Net Income
9.0%
Free Cash Flow
8.4%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.6
FCF per Share
$-0.4
Short interest
10.8%
Employees
17
Rev per Employee
$0.0

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Relmada Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Relmada Therapeutics Inc forecast:

Buy
90%
Hold
10%

Relmada Therapeutics Inc Events

Past Events
NOV
12
Q3 2026 Earnings Call
5 days ago
AUG
6
Q2 2026 Earnings Call
3 months ago
MAY
12
Q1 2026 Earnings Call
6 months ago
MAR
19
Q4 2025 Earnings Call
8 months ago
NOV
13
Q3 2025 Earnings Call
about one year ago

Financial data from Relmada Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
8% 8%
-
- Research and Development Expense 29 29
23% 23%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -65 -65
8% 8%
-
Net Profit -62 -62
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
2 days ago
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01 Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01
Neutral
GlobeNewsWire
●
5 days ago
NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance Long-term extension NDV-01 Phase 2 data demonstrate continued durability of response: 86% of 12-month complete responders remained in complete response at 18 months, with no Grade ≥3 treatment-related adverse events or discontinuations Registrational ...
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Mr. Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today